These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 23422645)

  • 21. Comparison of peginterferon and interferon in treating Chinese patients with chronic hepatitis C.
    Zhao S; Liu E; Yu H; Yang H; Xun M; Xue X; Song J; Xu K; Chu Y
    Hepatogastroenterology; 2008; 55(84):1047-54. PubMed ID: 18705326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study.
    Witthoeft T; Hueppe D; John C; Goelz J; Heyne R; Moeller B; Teuber G; Wollschlaeger S; Baumgarten A; Simon KG; Moog G; Dikopoulos N; Mauss S
    J Viral Hepat; 2010 Jul; 17(7):459-68. PubMed ID: 20158603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort.
    Aronsohn A; Ancuta I; Caruntu F; Coppola C; Delic D; Digiacomo A; Dusheiko GM; Lengyel G; Marcellin P; Orlandini A; Pruthi J; Silva GF; Tallarico L; Schmitz M; Tatsch F; Korner E; Cheinquer H
    J Viral Hepat; 2014 May; 21(5):377-80. PubMed ID: 24131506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
    Liu CH; Liu CJ; Huang CF; Lin JW; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Lee CY; Chen SI; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.
    Bruno R; Sacchi P; Cima S; Maiocchi L; Novati S; Filice G; Fagiuoli S
    J Viral Hepat; 2012 Jan; 19 Suppl 1():33-6. PubMed ID: 22233411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary study of two antiviral agents for hepatitis C genotype 1.
    Lok AS; Gardiner DF; Lawitz E; Martorell C; Everson GT; Ghalib R; Reindollar R; Rustgi V; McPhee F; Wind-Rotolo M; Persson A; Zhu K; Dimitrova DI; Eley T; Guo T; Grasela DM; Pasquinelli C
    N Engl J Med; 2012 Jan; 366(3):216-24. PubMed ID: 22256805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telaprevir for retreatment of HCV infection.
    Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
    N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
    N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
    Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
    Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
    Reddy KR; Shiffman ML; Morgan TR; Zeuzem S; Hadziyannis S; Hamzeh FM; Wright TL; Fried M
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):124-9. PubMed ID: 17196435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telaprevir for previously treated chronic HCV infection.
    McHutchison JG; Manns MP; Muir AJ; Terrault NA; Jacobson IM; Afdhal NH; Heathcote EJ; Zeuzem S; Reesink HW; Garg J; Bsharat M; George S; Kauffman RS; Adda N; Di Bisceglie AM;
    N Engl J Med; 2010 Apr; 362(14):1292-303. PubMed ID: 20375406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proceed with caution: peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials.
    Kershenobich D; Muñoz L; Malé R; Gaytan J; Sánchez F
    Hepatology; 2010 Dec; 52(6):2240-1; author reply 2241-2. PubMed ID: 21105116
    [No Abstract]   [Full Text] [Related]  

  • 36. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.
    Dogan UB; Akin MS; Yalaki S
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1317-20. PubMed ID: 23680912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sofosbuvir for previously untreated chronic hepatitis C infection.
    Lawitz E; Mangia A; Wyles D; Rodriguez-Torres M; Hassanein T; Gordon SC; Schultz M; Davis MN; Kayali Z; Reddy KR; Jacobson IM; Kowdley KV; Nyberg L; Subramanian GM; Hyland RH; Arterburn S; Jiang D; McNally J; Brainard D; Symonds WT; McHutchison JG; Sheikh AM; Younossi Z; Gane EJ
    N Engl J Med; 2013 May; 368(20):1878-87. PubMed ID: 23607594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
    Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ
    J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Alsaran K; Sabry A; Molhem A
    Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.